Try GOLD - Free
Can DPDPA's Research Exemption Power Private Sector Breakthroughs?
Bio Spectrum
|October 2025
India's Digital Personal Data Protection Act, 2023 (DPDPA), imposes uniform data protection obligations across sectors, significantly affecting healthcare, pharma, and biotech firms due to their use of sensitive personal data. Section 17(2) (b) provides limited exemptions for "research, archiving, or statistical purposes," which some stakeholders interpret as broad immunity.
-

This article challenges that view, arguing that Indian policy generally restricts exemptions for private, profit-driven research unless a clear public interest is demonstrated. Drawing on parallels with the GDPR, it concludes that the exemption will likely be narrowly construed, and the forthcoming DPDPA Rules are unlikely to support a wide carve-out.
The Digital Personal Data Protection Act, 2023 (DPDPA) is a law that primarily affects and benefits people and organisations that deal with personal data.
From tech giants to hospitals, from law firms to educational boards, the law places clear obligations on all those processing personal data. Healthcare, pharma, and biotech companies are no exception. While much attention has been drawn to how social media companies are affected, the impact on healthcare, pharma, and biotech sectors has not been adequately analysed.
Many such companies believe that the research exemption under Section 17(2)(b) of the DPDPA will save them from onerous compliance. But that belief may be flawed. In this article, we explain why.
The regulatory intent behind Sec. 17(2)(b) of DPDPA
Section 17(2)(b) allows personal data use for research, archiving, or statistics, if not tied to individuals and done per government norms.
It reads as:
- ‘(b) necessary for research, archiving or statistical purposes if the personal data is not to be used to take any decision specific to a Data Principal and such processing is carried on in accordance with such standards as may be prescribed.’
The “standards as may be prescribed” have not yet been prescribed, which means the exemption is not yet live. The rules for the DPDPA will propose standards and give other clarifications regarding the clause.
The direction of India’s public policy
This story is from the October 2025 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025

Bio Spectrum
Antara Senior Care names Mukesh Ghuraiya as Chief Marketing Officer
Antara Senior Care, a fully integrated senior care ecosystem, has appointed Mukesh Ghuraiya as the Executive Vice-President and Chief Marketing Officer (CMO).
1 min
October 2025
Bio Spectrum
Poly Medicure acquires PendraCare Group for Rs 188.5 Cr
Poly Medicure, a Delhi-based medical device company, has announced signing of definitive agreements to acquire 90 per cent stake in PendraCare Group consisting of PendraCare Holdings and Welling Medical from Welling Holdings B.V. at an Enterprise value of Rs 188.5 crore (Euro 18.3 million).
1 min
October 2025
Listen
Translate
Change font size